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Abstract
Childhood acute lymphoblastic leukemia (ALL) occurs more frequently in males. Reasons behind sex differences in childhood ALL
risk are unknown. In the present genome-wide association study (GWAS), we explored the genetic basis of sex differences by
comparing genotype frequencies between male and female cases in a case-only study to assess effect-modiﬁcation by sex.
The case-only design included 236 incident cases of childhood ALL consecutively recruited at the Texas Children’s Cancer Center
in Houston, Texas from 2007 to 2012. All cases were non-Hispanic whites, aged 1 to 10 years, and diagnosed with conﬁrmed B-cell
precursor ALL. Genotyping was performed using the Illumina HumanCoreExomeBeadChip on the Illumina Inﬁnium platform. Besides
the top 100 statistically most signiﬁcant results, results were also analyzed by the top 100 highest effect size with a nominal statistical
signiﬁcance (P<0.05).
The statistically most signiﬁcant sex-speciﬁc association (P=4  106) was with the single nucleotide polymorphism (SNP)
rs4813720 (RASSF2), an expression quantitative trait locus (eQTL) for RASSF2 in peripheral blood. rs4813720 is also a strong
methylation QTL (meQTL) for a CpG site (cg22485289) within RASSF2 in pregnancy, at birth, childhood, and adolescence.
cg22485289 is one of the hypomethylated CpG sites in ALL compared with pre-B cells. Two missense SNPs, rs12722042 and
12722039, in the HLA-DQA1 gene yielded the highest effect sizes (odds ratio [OR] ∼ 14; P<0.01) for sex-speciﬁc results. The HLA-
DQA1 SNPs belong to DQA1∗01 and conﬁrmed the previously reported male-speciﬁc association with DQA1∗01. This ﬁnding
supports the proposed infection-related etiology in childhood ALL risk for males. Further analyses revealed that most SNPs (either
direct effect or through linkage disequilibrium) were within active enhancers or active promoter regions and had regulatory effects on
gene expression levels.
Cumulative data suggested that RASSF2 rs4813720, which correlates with increased RASSF2 expression, may counteract the
suppressor effect of estrogen-regulated miR-17-92 on RASSF2 resulting in protection in males. Given the amount of sex hormone-
related mechanisms suggested by our ﬁndings, future studies should examine prenatal or early postnatal programming by sex
hormones when hormone levels show a large variation.
Abbreviations: ADAM28 = ADAM metallopeptidase domain 28, ALL = acute lymphoblastic leukemia, ARID5B = AT rich
interactive domain 5b, BCM = Baylor College of Medicine, CI = conﬁdence interval, eQTL = expression quantitative trait locus, ER =
estrogen receptor, ERCC1 = excision repair cross-complementation group 1, FDR = false discovery rate, FIU = Florida International
University, GSEA = gene set enrichment analysis, GWAS = genome-wide association study, H3K27ac = histone-3 lysine-
27acetylation, H3K4me1 = histone-3 lysine-4 monomethylation, H3K4me3 = histone-3 lysine-4 trimethylation, H3K9ac = histone-3
lysine-9 acetylation, HLA-DQA1 =major histocompatibility complex, class II, DQ alpha 1, HWE =Hardy–Weinberg equilibrium, IFNG
= interferon gamma, IRF1= interferon regulatory factor 1, KAT7=K(lysine) acetyltransferase 7, LD= linkage disequilibrium,meQTL=
methylation quantitative trait locus, MILE study = The Microarray Innovations in Leukemia study, NF = nuclear factor, OR = odds
ratio, QC = quality control, QQ = quantile-quantile, RAP1GAP2 = RAP1 GTPase activating protein 2, RASSF2 = Ras association
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domain family member 2, SCAN = SNP and copy number annotation, SNP = single nucleotide polymorphism, TFBS = transcription
factor binding sites, TXCCC = Texas Children’s Cancer Center, US = United States.
Keywords: acute lymphoblastic leukemia, case-only study, effect modiﬁcation, expression quantitative trait loci, gene expression
regulation, genome-wide association study, sex-speciﬁc association
1. Introduction
Acute lymphoblastic leukemia (ALL) is the most common
pediatric malignancy, with an annual incidence rate of 42 cases
per million children under age 15 in the United States.[1] While
overall 5-year survival rate has improved to 80% on average, the
US annual incidence rate increased by 0.8% per year from 1975
to 2012 in children aged 14 years and younger.[1,2]. Like many
other diseases and cancers, childhood ALL risk shows consistent
sex differences.[1,3–5] Males show a higher incidence rate in
comparison to females (45 cases per million children versus 39
cases per million children per year, respectively) in the United
States.[1] Relapse and secondary malignancies are also more
common in males.[6] Reasons underlying sex differences in
childhood ALL risk are still unknown, as it has not been
extensively evaluated.[4]
The sex difference in susceptibility to complex disorders is an
active research area, and some progress has been made in recent
years.[7,8] Studies that examined sex differential for etiological
clues identiﬁed several sex-speciﬁc genetic markers also for
childhood ALL risk.[9–14] For example, a study that examined
previously identiﬁed childhood ALL single nucleotide polymor-
phisms (SNPs) in genome-wide association studies (GWAS)[15,16]
reported sex-speciﬁc effects of 2 statistically correlated ARID5B
(AT-rich interactive domain 5b) SNPs (rs10994982 [P=0.01]
and rs10740055 [P=0.03]), with ALL risk in males (odds ratio
[OR]=3.79 and OR=4.35, respectively; ORs for females=1.03
and 1.37, respectively).[12] Candidate gene studies have also
reported sex differences in genetic associations in childhood ALL.
Two SNPs in ERCC1 (excision repair cross-complementation
group 1) are associated with childhood ALL risk among males,
but not with females.[13] Likewise, several multiple sclerosis risk
markers, such as HLA-DRA (rs3135388), HLA-C (rs9264942),
HSPA1B (rs1061581), and IFNG (rs2069727), also yielded sex-
speciﬁc associations with childhood ALL risk.[10] Associations
with an intronic SNP (rs12203592) in IRF4 and an intergenic
SNP (rs2395185) near HLA-DRA further suggest the existence
of sex-speciﬁc genetic risk variants.[9,11]
The robust and replicated sex-speciﬁc association with an
IFNG (interferon gamma) polymorphism (rs2069727; Pinteraction
=0.008) in asthma suggests the existence of genetic contribution
to sex differences in nonmalignant childhood disorders.[17] The
same SNP also shows a sex-speciﬁc association with childhood
ALL risk.[10] A recent genome-wide meta-analysis of asthma
revealed sex-speciﬁc candidate risk markers in interferon
regulatory factor 1 (IRF1) and RAP1 GTPase activating protein
2 (RAP1GAP2) with regulatory effects in gene regulation as
expression quantitative trait loci (eQTL).[18] Yao et al[19]
examined 11,672 disease-associated polymorphisms from the
National Human Genome Research Institute GWAS catalog and
dbGaP database in relation to gene expression levels in the whole
blood derived RNA and identiﬁed 14 sex-speciﬁc eQTLs. A
recent survey of correlations between SNPs and gene expression
levels by sex showed that up to 15% of autosomal SNPs have a
gender bias in their correlations.[20] Similarly, another study
reported that 582 autosomal genes have sex-speciﬁc differences
in their expression levels.[21] Such sex-speciﬁc signals are likely to
be diluted or cancelled out when both genders are analyzed
simultaneously. Likewise, reanalysis of GWAS datasets revealed
that coronary artery diseases, Crohn disease, rheumatoid
arthritis, and type1 diabetes show sex-speciﬁc associations with
increased risk in only 1 gender.[22,23] In the present GWAS, we
explored the genetic basis of sex differences by comparing
genotype frequencies between male and female cases with
childhood ALL using a case-only study design.
2. Materials and methods
2.1. Study design
We used a case-only design because of its greater statistical power
in detecting effect modiﬁcation, in this case, sex and genotype
interactions, in comparison to other traditional epidemiological
designs.[24] An assumption of the case-only design requires
genotype and sex to be independent in the healthy population.
There is no reason to believe that healthy male and female
controls have different genotype frequencies in autosomal
chromosomes. Recruitment of cases in a rare disease like
childhood ALL is a challenge; hence, preferring a statistically
more powerful research design was more practical.
2.2. Subject recruitment
Institutional review board approval was granted by Florida
International University (FIU), Ofﬁce of Research Integrity, and
Baylor College ofMedicine (BCM) prior to the study. Samples for
the current study were obtained from a parent case-control study
of childhood ALL and has been explained elsewhere in detail.[11]
Brieﬂy, incident cases of childhood ALL were consecutively
recruited at the Texas Children’s Cancer Center (TXCCC), BCM,
in Houston, Texas from 2007 to 2012. The present study used
236 cases from the parent study for the case-only analysis. They
were all non-Hispanic whites, aged 1 to 10 years, and diagnosed
with conﬁrmed B-cell precursor ALL. Genomic DNA was
extracted from blood samples at TXCCC, BCM. Established
childhood ALL risk associations identiﬁed in previous
GWAS[14–16] have been replicated to validate the parent case-
control study sample using TaqMan allelic discrimination assays
at FIU.[11]
2.3. Genotyping
Genotype data were generated using the Illumina Human-
CoreExome BeadChip (Illumina, San Diego, CA) on the Illumina
Inﬁnium platform at the John P. Hussman Institute of Human
Genomics, University of Miami, Florida.
2.4. Data analysis
Quality control (QC) steps were performed in a hierarchial
fashion using PLINK and R packages.[25] Sample QC was done
prior to SNP QC. The Hardy–Weinberg equilibrium (HWE)
test was used retrospectively in the whole group of subjects for
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sex-speciﬁc analysis. Unconditional logistic regression was used
to calculate allelic ORs and 95% conﬁdence intervals (CIs) after
coding males as cases and females as controls. The coding of male
and female cases for statistical analysis meant that an OR greater
than 1.0 indicates greater risk for males compared with females.
Power analysis and sample software was used to calculate
statistical power for various risk genotype frequencies. The study
was statistically powered to detect qualitative interactions, that is
sex-speciﬁc associations differing in direction (risk or protection);
rather than associations in the same direction and differing in
magnitude (quantitative interactions). Permutation testing
(10,000 permutations) was performed for all sex-speciﬁc results
to rule out chance ﬁndings using a threshold of P<0.05. Results
were adjusted for potential population stratiﬁcation using the
genomic control method.[26] A quantile-quantile (Q-Q) plot was
used to rule out systematic errors (Supplementary Figure 1, http://
links.lww.com/MD/B374). Besides the top 100 statistically most
signiﬁcant results (Supplementary Table 1, http://links.lww.com/
MD/B375), results were also analyzed by the OR with a nominal
statistical signiﬁcance (P<0.05) (Supplementary Table 2, http://
links.lww.com/MD/B376).
2.5. Bioinformatic analysis
To functionally annotate the SNPs that have shown sex-speciﬁc
associations, a number of bioinformatic tools were used. Variants
were annotated for their effects on the gene expression, protein,
and the predicted function using several bioinformatic and
empirical tools. ANNOVAR was used to obtain functionality
scores (DANN, FATHMM, GWAVA, SIFT, PolyPhen2, Muta-
tion Taster, Mutation Assessor, LRT, FATHMM, andMetaLR),
as well as conservation scores.[27] ANNOVAR and SNPnexus[28]
were used to predict the effect of variants on transcription factor
binding sites (TFBS), microRNA binding sites and identiﬁcation
of variants that disrupt enhancers, repressors, and promoters.
Complementary annotations were performed using CADD,[29]
RegulomeDB,[30] HaploReg v4,[31] SNiPA,[32] and rVarBase.[33]
GWAS3D was used to predict genetic variants or variants in
linkage disequilibrium (LD) affecting regulatory pathways and
essential disease/trait associations by integrating functional
genomics, chromatin state, sequence motif, and conservation
information.[34] It also provides visualization tools to compre-
hend the results. To assess correlations of SNPs with gene
expression levels in peripheral blood cells, we used SNP and Copy
Number Annotation (SCAN) database [35] and Blood eQTL [36]
databases. For each SNP, the Blood eQTL database and SCAN
provided information from experimental data on gene expression
regulation in peripheral blood cells and lymphoblastoid cell lines,
respectively. Likewise, we screened mQTLdb for methylation-
QTLs (meQTL) to examine effects of sex-speciﬁc variants on
CpG islands[37] at birth, during childhood and adolescence as
well as during pregnancy. Statistically similar (proxy) SNP sets
for each SNP were obtained from HaploReg v4,[31] and were
submitted to the tools listed above for a number of analyses. For
direct observation of TFBSs nearby SNPs, we examined the Swiss
Regulon browser.[38] Gene set enrichment analysis (GSEA) was
performed using DAVID v6.7.[39] The interactions of candidate
genes with other genes and noncoding RNAs were investigated
using NPinter v3.0,[40] which provides experimental data.
Computational miRNA targets on protein-coding genes were
explored using TargetScan.[41] To map theHLA-DQA1 SNPs to
HLA-DQA1 types, we examined complete sequences of HLA-
DQA1 alleles in the IPD-IMGT/HLA Database (http://www.ebi.
ac.uk/ipd/imgt/hla).
2.6. The microarray innovations in leukemia (MILE) study
The MILE study generated microarray-based gene expression
proﬁles from 2096 patients with standard subtypes of acute and
chronic leukemia (and myelodysplastic syndromes) in 11
laboratories on 3 continents.[42] The aim of the study was to
examine gene expression proﬁles for diagnosis and subclassiﬁca-
tion. The individual level data from the 2096 patients were
available to compare expression levels of different genes of
interest in different leukemia subtypes.
3. Results
After stringent QC, 209 subjects and 271,069 SNPs were
included in the statistical analysis. In the ﬁnal dataset, genotype
call rates were >99.9%. All QC steps and their results are
reported in Table 1. The ﬁnal sample included 116males (55.5%)
and 93 females (44.5%) with no statistically signiﬁcant difference
in age distribution (P=0.43). The mean age was 4.45 (±2.58)
years for males and 4.73 (±2.32) years for females. The genomic
inﬂation factor (l), an indicator of population stratiﬁcation, was
1.0, which suggested no population stratiﬁcation, as conﬁrmed
by the Q-Q plot (Supplementary Figure 1, http://links.lww.com/
MD/B374). The design was ideal to detect sex-speciﬁc associ-
ations as the reﬂection of allele frequencies higher in one sex
than the other. Naturally, the allele frequencies in the pooled
sample would be in between sex-speciﬁc frequencies. We checked
this assumption by using the frequencies for the European sample
in the HapMap project (Tables 2 and 3). At least for the higher
Table 1
Quality control steps for samples and SNPs.
QC steps Criteria for QC Numbers ﬁltered
Sample Sex discordant We used genetically identiﬁed sex information based on sex
chromosomes instead of reported sex information
5
Sample call rate Call rate 99% 14
Heterozygosity rate Autosomal heterozygosity rate outside of±3 standard deviations from the mean 8
Duplicate Samples excluded as duplicate (PI_HAT > 90%) 0
SNP Genotype call rate Call rate <99% 6261
MAF MAF 0.03 260,641∗
Missingness between males and females Differential missingness between males and females with P<1.0  103 478
HWE HWE (P<103) was used in the whole group 0
HWE=Hardy–Weinberg equilibrium, MAF=minor allele frequency, QC=quality control, SNP= single nucleotide polymorphism.
∗
These SNPs had very low allele frequencies and would be noninformative as they show little variation in the sample set being analyzed. Statistical power to detect associations with them was insufﬁcient.
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ranking results, HapMap frequencies were between the frequen-
cies observed in male and female cases.
When results were ranked according to their P values, the
smallest P value was 3.8  106 for RASSF2 (Ras association
domain family member 2), rs4813720 association, ORinteraction=
0.30) indicating males with the minor allele were less likely to
develop ALL compared with females with the minor allele
(Table 2 and Supplementary Table 1, http://links.lww.com/MD/
B375). The SNP rs4813720 correlates with RASSF2 expression
levels (P=2.1  106) in peripheral blood cells[36] (Supplemen-
tary Table 3, http://links.lww.com/MD/B377). Bioinformatic
analysis also yielded high functionality scores (CADD=5.13;
DANN=0.7). According to rVarBase analysis, this SNP maps to
active enhancers in highly relevant cell types: primary hemato-
poietic cells, primary B cells, primary T-helper cells, primary
neutrophils, and monocytes. HaploReg v4 analysis revealed that
a nearby (552bp away) SNP, rs7271897, is in LD with
rs4813720 (r2=0.70), and alters an estrogen receptor (ER)-
alpha binding site. Likewise, rs13045004 (within 3kb) is in LD
with rs4813720 (r2=0.70), and alters an NF-kB binding site. In
HaploReg analysis, there were 3 SNPs in strong LD (r2 ≥ 0.80)
with rs4813720, but most bioinformatic analyses predicted
rs4813720 as the putative causal SNP. An indel SNP rs3215695
was statistically correlated (r2=0.98) with rs4813720 yielding a
high functional score (2b) for RegulomeDB. This SNP is also
located in an active transcription start site.
Having observed that the statistically most signiﬁcant
association (RASSF2 rs4813720) was likely to be causal, we
performed extended in silico analysis of rs4813720. Besides being
an eQTL for RASSF2 in peripheral blood cells, this SNP is also
located within enhancers in cell types relevant to leukemia. Since
RASSF2 is frequently methylated in tumors,[43] we also examined
whether rs4813720 is a meQTL. Screening of the mQTLdb
showed that rs4813720 is a very strong meQTL for the CpG site
cg22485289 (Table 4) in the promoter region of RASSF2 at most
time points examined (pregnancy, birth, childhood, and adoles-
cence; P 9  1014), and at middle age, but not as signiﬁcantly
(P=2  1010).
Having established that our top hit rs4813720 is an eQTL for
RASSF2 and a meQTL for a CpG site within the same gene, we
examined whether it may be involved in any other mechanism
that would affect the expression levels of RASSF2. The
examination of the NPinter database revealed that RASSF2
physically interacts with mir-19a/19b. TargetScan also predicts
mir-19b binding to RASSF2 3’UTR. However, none of the SNPs
in the statistically similar SNP set of rs4813720 were within the
Table 2
SNPs associated with sex-speciﬁc childhood ALL risk at the signiﬁcance level P<10−4.
SNP Gene/region Chr
Minor
allele Location
MAF
(males)
HapMap
CEU MAF
MAF
(females)
ORallele
(95% CI)
∗
P value†
P value
(permutation)‡
rs4813720 RASSF2 20 A Intron 0.23 0.37 0.44 0.30 (0.18–0.50) 3.85  106 1.0  104
rs231237 HSPB6/PROSER3 19 A Intron 0.42 0.39 0.21 3.02 (1.87–4.89) 6.79  106 1.0  104
rs7323018 13q14.11 13 G Intergenic 0.17 0.32 0.36 0.30 (0.18–0.51) 7.42  106 1.0  104
rs17027254 2p22.1 2 T Intergenic 0.19 0.40 0.40 0.36 (0.23–0.58) 1.66  105 1.0  104
rs798292 MAGI2 7 G Intron 0.16 0.24 0.35 0.38 (0.24–0.60) 4.47  105 1.0  104
rs13107783 4p15.31 4 A Intergenic 0.32 0.51 0.52 0.40 (0.26–0.62) 5.21  105 1.0  104
rs7912381 10q26.3 10 G Intergenic 0.39 0.32 0.21 2.71 (1.67–4.51) 5.47  105 2.0  104
rs206457 18p11.22 18 T Intergenic 0.59 0.43 0.38 2.30 (1.53–3.45) 6.31  105 1.0  104
rs7723568 5p15.33 5 A Intergenic 0.35 0.30 0.17 2.77 (1.68–4.56) 6.66  105 1.0  104
rs1849374 12p11.22 12 A Intergenic 0.44 0.29 0.25 2.49 (1.59–3.92) 7.20  105 2.0  104
rs506389 8q22.3 8 A Intergenic 0.28 0.19 0.11 3.00 (1.74–5.17) 7.99  105 2.0  104
rs349714 3p25.3 3 T Intergenic 0.45 0.50 0.26 2.45 (1.57–3.83) 8.60  105 1.0  104
ALL=acute lymphoblastic leukaemia, CEU=European sample in HapMap project, Chr= chromosome, MAF=minor allele frequency, SNP= single nucleotide polymorphism.
∗
Interaction odds ratio per allele (ORallele) for the additive model.
† P value adjusted for genomic control.
‡ P value permutation=point-wise P value from maxT permutation analysis after 10,000 permutation.
Table 3
SNPs with the highest effect sizes (OR>10; P<0.05) showing sex-speciﬁc associations with childhood ALL risk.
SNP Gene/region Chr
Minor
allele Location
MAF
(males)
HapMap
CEU MAF
MAF
(females)
ORallele
(95% CI)
∗
P value†
P value
(permutation)‡
rs12722042 HLA-DQA1 6 G Exon 0.07 0.04 0.005 14.72 (1.91–113.2) 0.008 6.0  104
rs11992342 ADAM28 8 T Intron 0.07 0.04 0.005 14.72 (1.91–113.9) 0.01 0.001
rs12722039 HLA-DQA1 6 A Exon 0.07 0.04 0.005 14.08 (1.84–107.5) 0.009 5.0  104
rs80040922 UMODL1 21 A Exon 0.06 0.04 0.005 13.66 (1.77–105.5) 0.01 0.001
rs61753605 PRIM2 6 C Exon 0.06 0.02 0.005 13.37 (1.73–103.2) 0.01 0.002
rs35665085 CECR5 22 G Exon 0.06 0.05 0.005 12.63 (1.63–97.92) 0.02 0.003
rs143021649 CNTN3 3 T Exon 0.06 0.04 0.005 11.61 (1.49–90.50) 0.02 0.003
rs6795524 PROS1 3 G Intron 0.05 0.006 0.005 10.62 (1.35–83.22) 0.02 0.008
rs10003468 4q28.1 4 C Intergenic 0.05 0.02 0.005 10.62 (1.35–83.22) 0.02 0.006
ALL=acute lymphoblastic leukaemia, CEU=European sample in the HapMap project, Chr= chromosome, MAF=minor allele frequency, OR= odds ratio, SNP= single nucleotide polymorphism.
∗
Interaction odds ratio per allele (ORallele) for the additive model.
† P value adjusted for genomic control.
‡ P value permutation=point-wise P value from maxT permutation analysis after 10,000 permutation.
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microRNA binding site in 3’ UTR. To gain further insight into
RASSF2 function, we obtained the list of experimentally
conﬁrmed target gene list for mir-19a/19b (n=298) fromNPinter
database, and subjected this list to GSEA on DAVID. The highest
fold enrichment (12.4) was observed for RAS association
category, which was also the statistically most signiﬁcant (false
discovery rate [FDR]=0.004). Apoptosis was also one of the
most highly signiﬁcant categories (fold enrichment=3.5; FDR=
0.007). Thus, the only microRNA that had an experimentally
conﬁrmed physical interaction with RASSF2 had targets
cumulatively involved in RAS signaling and apoptosis (mir-
19a/19b belongs to the mir-17-92 cluster).
The second ranking SNP rs23127 (ORinteraction=3.0),
located in the genes PROSER3/HSPB6, yielded a high risk
for males compared with females for childhood ALL (Table 2).
Our analysis suggested that rs23127 might have multiple
regulatory functions as it affects the expression level of several
genes (COX6B1; P=2.2  106, UPK1A; P=1.2  107 and
U2AF1LA; P=3.1 x 109) (Supplementary Table 3, http://
links.lww.com/MD/B377) and is also located in an active
promoter region (RegulomeDB=2b; CADD=7.8; DANN=
0.71). Another top ranking SNP, rs798292, is associated
with expression of KAT7 (K(lysine) acetyltransferase 7),
a histone acetyltransferase that represses androgen receptor-
mediated transcription in lymphoblastoid cells[36] (Supplemen-
tary Table 3, http://links.lww.com/MD/B377). Results
ranked by statistical signiﬁcance showed more eQTLs in
lymphoblastoid cell lines in comparison to the results based
on effect size (Supplementary Table 3, http://links.lww.com/
MD/B377).
Table 4
SNPswith sex-speciﬁc associations, their meQTL status (for childhood period) and target CpG sites,[37] and the status of DNAmethylation
in ALL and healthy pre-B cells.[50].
SNP
Target CpG
ID (Gene) P value
∗
meQTL effect
size (regression
beta value)
ALL mean
methylation
pre-B
cells mean
methylation
DNA
methylation
status in ALL
Genetic association
effect size
(odds ratio)
rs4813720† cg22485289 (RASSF2) 8.3  1023 0.432 0.279 0.764 Hypomethylation 0.30
rs8106959† cg14120049 (HSPB6) 6.6  1021 0.867 0.651 0.344 Hypermethylation 2.95
rs11708505† cg24363020 (SHQ1) 1.4  1060 0.591 0.505 0.873 Hypomethylation 0.48
rs7407281† cg11957475 (PMAIP1) 8.4  1016 0.420 0.883 0.600 Hypermethylation 2.70
rs11011225† cg25427524 5.1  1015 0.453 ND ND ND .
rs11011225† cg02535924 1.6  1015 0.472 ND ND ND .
rs719569† cg02535924 1.6  1089 0.775 ND ND ND .
rs719569† cg25427524 3.7  1071 0.689 ND ND ND .
rs719569† cg17830980x 3.7  1039 0.482 ND ND ND .
rs719569† cg00637047 6.9  1030 0.278 ND ND ND .
rs719569† cg00409905 3.7  1028 0.406 ND ND ND .
rs719569† cg01217720x 2.3  1018 0.326 ND ND ND .
rs719569† cg12163508 4.1  1018 0.362 ND ND ND .
rs719569† cg23533926x 4.7  1017 0.259 ND ND ND .
rs719569† cg18963800 4.8  1015 0.326 ND ND ND .
rs719569† cg27523141x 1.7  1014 0.269 ND ND ND .
rs719569† cg26666804x 3.2  1014 0.287 ND ND ND .
rs719569† cg20499290 (ZNF33BP1) 4.6  1017 0.340 0.774 0.394 Hypermethylation 0.48
rs12256543† cg20499290x (ZNF33BP1) 1.2  1014 0.318 0.774 0.394 Hypermethylation 2.07
rs12256543† cg25427524 4.0  10112 0.836 ND ND ND .
rs12256543† cg02535924 6.8  1066 0.692 ND ND ND .
rs12256543† cg17830980x 2.3  1032 0.446 ND ND ND .
rs12256543† cg00637047 4.9  1026 0.263 ND ND ND .
rs12256543† cg00409905 1.4  1024 0.385 ND ND ND .
rs12256543† cg12163508 2.6  1024 0.427 ND ND ND .
rs12256543† cg01217720x 7.2  1023 0.370 ND ND ND .
rs12256543† cg23533926x 5.6  1022 0.299 ND ND ND .
rs12256543† cg18963800 2.3  1020 0.387 ND ND ND .
rs12256543† cg26666804x 9.5  1020 0.346 ND ND ND .
rs12256543† cg04469686x 6.5  1016 0.342 ND ND ND .
rs12256543† cg25373794x 2.1  1015 0.333 ND ND ND .
rs12256543† cg25951256 3.6  1014 0.328 ND ND ND .
rs7195089‡ cg05797001 1.1  1025 0.949 ND ND ND .
rs7195089‡ cg07982935 1.7  1021 0.864 ND ND ND .
rs7195089‡ cg27232078 (CHST5) 6.1  1015 0.782 0.851 0.592 Hypermethylation 5.80
rs2233805‡ cg27232078 (CHST5) 1.4  1015 0.814 0.851 0.592 Hypermethylation 4.77
rs2233805‡ cg05797001 2.1  1026 0.980 ND ND ND .
rs2233805‡ cg07982935 7.2  1023 0.908 ND ND ND .
ALL=acute lymphoblastic leukaemia, ND=no data, SNP= single nucleotide polymorphism.
∗
meQTL P value (statistical signiﬁcance threshold  5  1014).[37]
† Sex-speciﬁc variants based on statistical signiﬁcance.
‡ Sex-speciﬁc variants based on effect size.
x Trans-meQTL (target CpG sites are on chromosomes different from the chromosome the SNP is located, or more than 500kb away from the SNP on the same chromosome.[37] Gene names and odds ratios are
shown only for the SNPs with statistically signiﬁcant methylation differences in ALL.
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Table 3 and Supplementary Table 2 (http://links.lww.com/
MD/B376) show the results based on the highest effect sizes. Two
statistically correlated SNPs (r2=1), rs12722042 (CADD=16.02
and DANN=1) and rs12722039 (CADD=5.02 and DANN=
0.49), from theHLA-DQA1 (major histocompatibility complex,
class II, DQ alpha 1) gene and a SNP, rs11992342, from the
ADAM28 (ADAM metallopeptidase domain 28) region yielded
the highest effect sizes (ORinteraction > 14; P 0.01) for sex-
speciﬁc results. Both HLA-DQA1 SNPs were missense variants
and marked by several histone modiﬁcation marks, such as
Histone-3 lysine-4 monomethylation (H3K4me1), Histone-3
lysine-4 trimethylation (H3K4me3), Histone-3 lysine-9 acetyla-
tion (H3K9ac), and Histone-3 lysine-27acetylation (H3K27ac)
indicating the location within an active promoter site. When we
examined whether there are crucial TFBSs in the vicinity of these
SNPs located at chromosome 6 positions 32,605,284 and
32,605,309 (hg19 coordinates), Swiss Regulon browser indicated
that there was an androgen receptor binding site within 100bp of
these SNPs (32,605,225 to 32,605,2546). ADAM28 rs11992342
maps to an active enhancer region, and affects binding afﬁnity of
several TFs of STAT family. Top ranking 100 results based onOR
included associations with more missense variants than the results
based on P values (34 vs 2) (Supplementary Tables 1 and 2, http://
links.lww.com/MD/B375, http://links.lww.com/MD/B376). Our
results predicted several of these missense variants may have
deleterious effects on ﬁnal protein structure (Supplementary
Table 4, http://links.lww.com/MD/B378). Most of the identiﬁed
sex-speciﬁc SNPs were located in cis-regulatory elements, such as
promoters and enhancers or may have eQTL effects (Supplemen-
tary Tables 1 and 2, http://links.lww.com/MD/B375, http://links.
lww.com/MD/B376).
Our mQTLdb screening results showed that several variants
were meQTLs at birth, during childhood and adolescence, as well
as during pregnancy (Supplementary Table 5, http://links.lww.
com/MD/B379). We examined the involvement of the CpG sites
linked to our GWAS associations in B-cell differentiation and
leukemogenesis by using the data provided by Kulis et al.[50] A
total of 24 variants were reported to be pivotal for B-lymphocyte
differentiation and their target CpG sites found to be either
hypermethylated or hypomethylated in ALL (Table 4). Most
notably, the top ranking SNP rs4813720 is an meQTL for the
CpG island cg22485289 within RASSF2. Both HLA-DQA1
SNPs (rs12722042 and rs12722039) are meQTLs for the CpG
island cg24593918 within HLA-DQB1.
GWAS3D analysis for the top 100 ranking sets of SNPs
unraveled a number of long-range interactions between the regions
of SNP locations and other genes, some ofwhich being on different
chromosomes (Supplementary Figures 2 and 3, http://links.lww.
com/MD/B374). GWAS3D reported 84 variants with TF binding
afﬁnity changes or regulatory signals based on the GM12878 cell
line and HapMap CEU population for 100 statistically most
signiﬁcant results. A total of 66 variants have been detected
affecting long-range interactions (Supplementary Figure 2, http://
links.lww.com/MD/B374). Cumulatively, GWAS3D results sug-
gested a potential role for STATandMYCTFs in sex-differences in
childhoodALLrisk.Among the top100 results rankedby the effect
size, GWAS3D analysis showed that 68 of the variants were
associated with regulatory signals and TF binding afﬁnity changes
on the GM12878 cell line and HapMap CEU population. Long-
range interactions were noted for 60 variants (Supplementary
Figure 3, http://links.lww.com/MD/B374).
As shown in Table 5, in all ALL subtypes examined in the
MILE study, RASSF2 expression was lower than controls, and T
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mir-17-92 levels were higher with statistical signiﬁcance varying
from P=0.02 to 6.8  1080. The statistically most signiﬁcant
change in RASSF2 was in T-ALL with the expression ratio to
controls being 0.23 (mir-17-92 showed an expression ratio of
1.71 in T-ALL). The statistically most signiﬁcant change in mir-
17-92 was in ALL with t(12;21) with the expression ratio to
controls being 3.17 (RASSF2 showed an expression ratio of 0.50
in the same ALL subtype). In all subtypes, RASSSF2 and mir-17-
92 expression levels showed an inverse correlation (Table 5). The
expression levels ofMYC did not appear to correlate withmir-17-
92 levels except in pro-B and mature B-ALL subtypes (Table 5).
While the strong inverse correlation between RASSF2 and mir-
17-92 conﬁrmed the expected relationship between them, the
lack of a correlation betweenMYC and mir-17-92 suggested that
mir-17-92 increase in ALL is not exclusively caused byMYC, but
may be due to genomic ampliﬁcations as observed in other
malignancies.[45]
4. Discussion
This is the ﬁrst GWAS designed to identify sex-speciﬁc childhood
ALL risk markers. As a second exploratory approach, we also
analyzed results based on OR, to examine clinically meaningful
results that may not have reached the strict statistical signiﬁcance
due to their lower frequencies. These results are free from
multiple comparison issues, as each permutation on each SNP
assesses the role of chance.
The statistically most signiﬁcant association was with an
intronic SNP in RASSF2, which is a novel tumor suppressor gene
and a member of the RAS family which regulates a wide range of
biological processes, including KRAS signaling.[46,47] It induces
apoptosis and cell cycle arrest, shows frequent methylation in
several cancers, and rs4813720 correlates with RASSF2 expres-
sion levels.[48]RASSF2 ablation down regulates genes involved in
the immune response, hematological development, as well as
genes activating nuclear factor (NF)-kB signaling.[46]
RASSF2 has emerged as a candidate gene involved in sex-
speciﬁc modiﬁcation of risk for childhood ALL in the present
study for the ﬁrst time. This result is biologically plausible.
RASSF2 is a tumor suppressor gene via its inhibitory effect
on the proto-oncogene KRAS.[43]KRAS is one of the most
frequently mutated proto-oncogenes in childhood ALL.[44,49]
The top ranking sex-speciﬁc risk marker for childhood ALL,
rs4813720, correlates with RASSF2 expression level,[36] as well
as themethylation levels in a key CpG site cg22485289within the
promoter of RASSF2 at birth and childhood.[37] This particular
CpG site is one of the key sites found to be hypomethylated in
childhood ALL compared with pre-B cells.[50] Thus, rs4813720
appears to be involved in the prevention of childhood ALL in
males via maintaining the expression levels of tumor suppressive
RASSF2 in pre-B cells presumably via a methylation-related
mechanism. Linkage of DNA methylation quantitative trait loci
to human cancer risk is already well documented,[48] and our
results represent yet another example.
The sex effect in the prevention of childhood ALL by RASSF2
expression may also be biologically plausible. The key to the sex
effect may be the events upstream of RASSF2. The miR-17-92
cluster, which is in an ampliﬁed genomic region in human
malignant B-cell lymphomas, has been shown to be an
oncomicroRNA also in c-Myc-induced lymphomagenesis in
mice.[51] mir-17-92 also plays a major role in normal B-cell
development.[52,53] In an experimental study, RASSF2 has been
found to be a target gene for the mir-92 polycistron.[54] Our
bioinformatics work also conﬁrmed a physical interaction with
one of the micro RNAs that derive from mir-17-92 polycistron,
mir-19a/19b, and revealed a predicted binding site for it (see
Results). Crucially, estrogen administration increases mir-17-92
levels viaMYC overexpression[55,56] and downregulates RASSF2
expression.[57] Thus, in addition to the already known involve-
ment of sex hormones in the gender effect in cancer,[58] we
propose a novel mechanism for childhood ALL: estrogen
exposure increases the oncogenic microRNA species mir-19a/
19b levels, which in turn downregulates RASSF2 (as well as
another tumor suppressor PTEN[59]). Downregulation of
RASSF2 abolishes KRAS inhibition, and the KRAS oncogene
contributes to childhood ALL development. Males are already
less susceptible to this mechanism due to lesser exposure to
estrogen, as well as due to the presence of binding sites to Y
chromosome-linked transcription factor SRY,[47] and are further
protected if they possess the minor allele of rs4813720, which
increases RASSF2 expression levels. If experimentally conﬁrmed,
this would be the ﬁrst demonstration of the mechanism of a
sexually antagonistic association of a SNP with cancer
susceptibility. Although sex hormone levels are very low during
childhood in both males and females, programming of autosomal
gene expression by sex hormones during prenatal development or
during the temporary androgen surge in early infancy (called
mini-puberty) is a possibility. Mini-puberty is particularly
interesting as inter individual variability in sex hormone levels,
which may rise to the puberty levels but temporarily, may be very
remarkable.[60,61] Unfortunately, there are no studies on the long-
term effects of these sex hormone exposures in early infancy on
biological systems although behavioral studies continue to show
the relevance of this exposure.[60,62]
Having a marker that is associated with prevention for
childhood ALL in males has clinical importance. Males develop
childhood ALL more frequently, have a higher relapse rate, and
worse prognosis.[4] Due to having clinically more aggressive form
of the disease, they also receive more intensive treatment resulting
in higher toxicity. The marker is within RASSF2 and acts by
increasing its expression, which in turn, binds to and inactivates
KRAS. KRAS is frequently mutated in childhood ALL[44,49] and
mutant KRAS worsens the prognosis.[49] Thus, any pharmaco-
logical intervention to increase the expression of RASSF2 should
be beneﬁcial for male patients with childhood ALL, especially for
those with KRAS mutations, to counter the deleterious effects of
mutant KRAS.
Examination of associations with the highest odds ratios
identiﬁed a pair of HLA region SNPs. The HLA-DQA1 SNPs
(rs12722042 and rs12722039) belong toDQA1∗01, conﬁrming
the previously reported male-speciﬁc association with
DQA1∗01, and supporting the proposed infection-related
etiology in childhood ALL risk for males.[63] Both HLA-
DQA1 SNPs are located in an active promoter region and
showed eQTL effects on theHLA-DQB1 gene. These SNPs have
regulatory effects on gene expression rather than on protein
structure. Intriguingly, the HLA-DQA1 SNPs are in close
proximity (<100bp) of an androgen receptor binding site. This
observation may be relevant in their risk associations with
childhood ALL in males. The SNP rs35597309, correlated
statistically with rs12722042 (r2=0.97), has shown a risk
association with esophageal squamous cell carcinoma in a
Chinese population[64] (esophageal carcinoma has a high male-
to-female ratio).
The validity of the case-only design depends on the indepen-
dence of exposure and genotype.[24] Departures from this
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independence may affect the results. Such an association would
be invalid due to the violation of the major assumption of case-
only approach. In the case of gender, it seems unlikely to have
different genotype frequencies in autosomal chromosomes
between males and females in the healthy population.[65]
Conforming to the assumptions of the case-control design still
does not make the results valid until replicated by a second
independent study. The lack of a previously observedassociationof
RASSF2 SNPs with childhood ALL does not argue against the
validity of our result. This is most likely due to cancellation of
associations in opposite directions in males and females when the
analysis is performed on the overall sample. None of the previous
childhoodALLGWASperformed sex-speciﬁc analyses.Despite the
biological plausibility of our results, given the limited sample size of
our study and lack of replication, it is important to reexamine these
results in an independent study before proceeding to functional
studies. These results cannot be generalized in any other ethnic
population, as all of these samples were non-Hispanic whites.
In conclusion, our results suggest that novel sex-speciﬁc risk
variants for childhood ALL exist. Functional analyses suggest
that most variants (either direct effect or through LD) have
regulatory effects, which increases the likelihood of causal
associations. For instance, the statistically most signiﬁcant
association rs4813720 correlates with RASSF2 expression and
may play a signiﬁcant role in childhoodALL etiology.Our results
also conﬁrm the previously observed male-speciﬁc association
withDQA1∗01. While ranking results by OR is not a traditional
approach for GWAS, this exploratory approach yielded several
missense variants with effects on protein function. The statisti-
cally most signiﬁcant association was with a SNP within
RASSF2, which interacts with KRAS. Given the difﬁculties of
developing drugs to inactivateKRAS directly,[66] the demonstra-
tion of the effect of RASSF2 in prevention from childhood ALL
may even offer a new target for drug development efforts.
Feasibility of countering the downstream effects of mir-17–92 by
pharmacological manipulation has already been shown.[67]
Prenatal programming by sex hormones, if conﬁrmed, may
shed some light on the mechanism of the differential risk with
childhood ALL. These preliminary results provide a foundation
for further replication and functional studies to examine the
genetic basis of sex-differential in childhood ALL risk. Future
studies should include functional and genetic replication of the
RASSF2 association, particularly in case series with known
KRAS mutation status. Given the well-established involvement
of the oncogenic mir-17-92 in its development and the more
exaggerated male predominance, childhood non-Hodgkin
lymphoma should also be examined for RASSF2 associa-
tions.[67,68]
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